316 related articles for article (PubMed ID: 19115412)
1. Contribution of the striatum to the effects of 5-HT1A receptor stimulation in L-DOPA-treated hemiparkinsonian rats.
Bishop C; Krolewski DM; Eskow KL; Barnum CJ; Dupre KB; Deak T; Walker PD
J Neurosci Res; 2009 May; 87(7):1645-58. PubMed ID: 19115412
[TBL] [Abstract][Full Text] [Related]
2. Effects of 5-HT1A receptor stimulation on D1 receptor agonist-induced striatonigral activity and dyskinesia in hemiparkinsonian rats.
Dupre KB; Ostock CY; George JA; Eskow Jaunarajs KL; Hueston CM; Bishop C
ACS Chem Neurosci; 2013 May; 4(5):747-60. PubMed ID: 23496922
[TBL] [Abstract][Full Text] [Related]
3. Striatal 5-HT1A receptor stimulation reduces D1 receptor-induced dyskinesia and improves movement in the hemiparkinsonian rat.
Dupre KB; Eskow KL; Barnum CJ; Bishop C
Neuropharmacology; 2008 Dec; 55(8):1321-8. PubMed ID: 18824001
[TBL] [Abstract][Full Text] [Related]
4. Local modulation of striatal glutamate efflux by serotonin 1A receptor stimulation in dyskinetic, hemiparkinsonian rats.
Dupre KB; Ostock CY; Eskow Jaunarajs KL; Button T; Savage LM; Wolf W; Bishop C
Exp Neurol; 2011 Jun; 229(2):288-99. PubMed ID: 21352823
[TBL] [Abstract][Full Text] [Related]
5. Effects of coincident 5-HT1A receptor stimulation and NMDA receptor antagonism on L-DOPA-induced dyskinesia and rotational behaviors in the hemi-parkinsonian rat.
Dupre KB; Eskow KL; Steiniger A; Klioueva A; Negron GE; Lormand L; Park JY; Bishop C
Psychopharmacology (Berl); 2008 Jul; 199(1):99-108. PubMed ID: 18545986
[TBL] [Abstract][Full Text] [Related]
6. Diverse serotonin actions of vilazodone reduce l-3,4-dihidroxyphenylalanine-induced dyskinesia in hemi-parkinsonian rats.
Meadows SM; Conti MM; Gross L; Chambers NE; Avnor Y; Ostock CY; Lanza K; Bishop C
Mov Disord; 2018 Nov; 33(11):1740-1749. PubMed ID: 30485908
[TBL] [Abstract][Full Text] [Related]
7. Role of the primary motor cortex in L-Dopa-induced dyskinesia and its modulation by 5-HT1A receptor stimulation.
Ostock CY; Dupre KB; Jaunarajs KL; Walters H; George J; Krolewski D; Walker PD; Bishop C
Neuropharmacology; 2011 Sep; 61(4):753-60. PubMed ID: 21635907
[TBL] [Abstract][Full Text] [Related]
8. Activity of serotonin 5-HT(1A) receptor 'biased agonists' in rat models of Parkinson's disease and L-DOPA-induced dyskinesia.
Iderberg H; McCreary AC; Varney MA; Cenci MA; Newman-Tancredi A
Neuropharmacology; 2015 Jun; 93():52-67. PubMed ID: 25645393
[TBL] [Abstract][Full Text] [Related]
9. Effects of 5-HT1A receptor stimulation on striatal and cortical M1 pERK induction by L-DOPA and a D1 receptor agonist in a rat model of Parkinson's disease.
Lindenbach D; Dupre KB; Eskow Jaunarajs KL; Ostock CY; Goldenberg AA; Bishop C
Brain Res; 2013 Nov; 1537():327-39. PubMed ID: 24060645
[TBL] [Abstract][Full Text] [Related]
10. The novel 5-HT1A receptor agonist, NLX-112 reduces l-DOPA-induced abnormal involuntary movements in rat: A chronic administration study with microdialysis measurements.
McCreary AC; Varney MA; Newman-Tancredi A
Neuropharmacology; 2016 Jun; 105():651-660. PubMed ID: 26777281
[TBL] [Abstract][Full Text] [Related]
11. Modulating mGluR5 and 5-HT1A/1B receptors to treat l-DOPA-induced dyskinesia: effects of combined treatment and possible mechanisms of action.
Iderberg H; Rylander D; Bimpisidis Z; Cenci MA
Exp Neurol; 2013 Dec; 250():116-24. PubMed ID: 24029003
[TBL] [Abstract][Full Text] [Related]
12. Characterizing the differential roles of striatal 5-HT
Meadows SM; Chambers NE; Conti MM; Bossert SC; Tasber C; Sheena E; Varney M; Newman-Tancredi A; Bishop C
Exp Neurol; 2017 Jun; 292():168-178. PubMed ID: 28342749
[TBL] [Abstract][Full Text] [Related]
13. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
Muñoz A; Li Q; Gardoni F; Marcello E; Qin C; Carlsson T; Kirik D; Di Luca M; Björklund A; Bezard E; Carta M
Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677
[TBL] [Abstract][Full Text] [Related]
14. NLX-112, a novel 5-HT1A receptor agonist for the treatment of L-DOPA-induced dyskinesia: Behavioral and neurochemical profile in rat.
Iderberg H; McCreary AC; Varney MA; Kleven MS; Koek W; Bardin L; Depoortère R; Cenci MA; Newman-Tancredi A
Exp Neurol; 2015 Sep; 271():335-50. PubMed ID: 26037043
[TBL] [Abstract][Full Text] [Related]
15. MDMA and fenfluramine reduce L-DOPA-induced dyskinesia via indirect 5-HT1A receptor stimulation.
Bishop C; Taylor JL; Kuhn DM; Eskow KL; Park JY; Walker PD
Eur J Neurosci; 2006 May; 23(10):2669-76. PubMed ID: 16817869
[TBL] [Abstract][Full Text] [Related]
16. Role of dopamine D3 and serotonin 5-HT 1A receptors in L: -DOPA-induced dyskinesias and effects of sarizotan in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Gerlach M; Bartoszyk GD; Riederer P; Dean O; van den Buuse M
J Neural Transm (Vienna); 2011 Dec; 118(12):1733-42. PubMed ID: 21253782
[TBL] [Abstract][Full Text] [Related]
17. Cellular and behavioral effects of 5-HT1A receptor agonist 8-OH-DPAT in a rat model of levodopa-induced motor complications.
Ba M; Kong M; Ma G; Yang H; Lu G; Chen S; Liu Z
Brain Res; 2007 Jan; 1127(1):177-84. PubMed ID: 17113046
[TBL] [Abstract][Full Text] [Related]
18. The role of the dorsal raphe nucleus in the development, expression, and treatment of L-dopa-induced dyskinesia in hemiparkinsonian rats.
Eskow KL; Dupre KB; Barnum CJ; Dickinson SO; Park JY; Bishop C
Synapse; 2009 Jul; 63(7):610-20. PubMed ID: 19309758
[TBL] [Abstract][Full Text] [Related]
19. Effects of prolonged selective serotonin reuptake inhibition on the development and expression of L-DOPA-induced dyskinesia in hemi-parkinsonian rats.
Conti MM; Ostock CY; Lindenbach D; Goldenberg AA; Kampton E; Dell'isola R; Katzman AC; Bishop C
Neuropharmacology; 2014 Feb; 77():1-8. PubMed ID: 24067924
[TBL] [Abstract][Full Text] [Related]
20. L-stepholidine reduced L-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease.
Mo J; Zhang H; Yu LP; Sun PH; Jin GZ; Zhen X
Neurobiol Aging; 2010 Jun; 31(6):926-36. PubMed ID: 18707801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
